Research Protocol

BPC-157 (10mg) — Research Protocol

Dosage Calculator → How to Reconstitute →

Quickstart Highlights

TB‑500 is a synthetic peptide fragment corresponding to the active region of thymosin beta‑4 (Tβ4), a naturally occurring 43‑amino‑acid protein involved in tissue repair and regeneration[1][2]. This educational protocol presents a once‑daily subcutaneous approach using a practical dilution for accurate insulin‑syringe measurements in research settings.

  • Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
  • Typical daily range: 500–1000 mcg once daily (gradual titration recommended).
  • Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U‑100 insulin syringe.
  • Storage: Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); do not freeze reconstituted solution.

Dosing & Reconstitution Guide

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Phase Dose Units (per injection)
Weeks 1–2 500 mcg 15 units (0.15 mL)
Weeks 3–4 600 mcg 18 units (0.18 mL)
Weeks 5–8 750 mcg 23 units (0.23 mL)
Weeks 9–12 1000 mcg 30 units (0.30 mL)

 

Frequency: Inject once daily subcutaneously. This schedule uses the largest practical dilution (3.0 mL) to keep per‑injection units in a comfortable range for accurate measurement. Total weekly dose averages ~5 mg, consistent with research protocols[3][4].

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label with date and concentration; refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration.

  • Peptide Vials (TB‑500, 10 mg each): 
    • 8 weeks ≈ 4 vials
    • 12 weeks ≈ 7 vials
    • 16 weeks ≈ 10 vials
  • Insulin Syringes (U‑100):
    • Per week: 7 syringes (1/day)
    • 8 weeks: 56 syringes
    • 12 weeks: 84 syringes
    • 16 weeks: 112 syringes
  • Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution
    • 8 weeks (4 vials): 12 mL → 2 × 10 mL bottles
    • 12 weeks (7 vials): 21 mL → 3 × 10 mL bottles
    • 16 weeks (10 vials): 30 mL → 3 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the injection site each day.
    • Per week: 14 swabs (2/day)
    • 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
    • 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
    • 16 weeks: 224 swabs → recommend 3 × 100‑count boxes

Protocol Overview

Protocol Overview

Concise summary of the once‑daily regimen.

  • Goal: Support tissue repair, wound healing, and angiogenesis through the active thymosin beta‑4 fragment mechanism[5][6].
  • Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if research goals require).
  • Dose Range: 500–1000 mcg daily with gradual titration (~5 mg/week average).
  • Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
  • Storage: Lyophilized frozen; reconstituted refrigerated; avoid freeze–thaw cycles of reconstituted solution.

Dosing Protocol

Suggested daily titration approach.

  • Start: 500 mcg daily; increase by ~100–150 mcg every 2 weeks as tolerated.
  • Target: 750–1000 mcg daily by Weeks 5–12.
  • Frequency: Once per day (subcutaneous).
  • Cycle Length: 8–12 weeks; optional extension to 16 weeks based on research protocol.
  • Timing: Any consistent time daily; rotate injection sites systematically.

Storage Instructions

Proper storage preserves peptide quality and activity.

  • Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure[7].
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); do not freeze reconstituted solution as freezing can denature peptides.
  • Allow vials to reach room temperature before opening to reduce condensation uptake.
  • Use reconstituted vials within 28 days when stored with bacteriostatic water preservative[8].

How It Works

TB‑500 represents the N‑terminal active fragment of thymosin beta‑4, specifically the heptapeptide sequence Ac‑LKKTETQ[1][2]. This region is responsible for the actin‑binding and cell‑migration properties of the full thymosin molecule. Preclinical studies demonstrate that TB‑500 promotes angiogenesis, accelerates wound healing, and supports tissue regeneration by upregulating cell motility and blood vessel formation[5][6]. Research in animal models shows enhanced collagen deposition and reduced healing time in injury sites treated with thymosin fragments[11]. Recent metabolic studies suggest TB‑500 may act as a prodrug, cleaving to an active pentapeptide metabolite that drives biological activity[12].

Potential Benefits & Side Effects

Observations from preclinical and veterinary literature.

  • Supports accelerated wound healing and tissue repair through enhanced angiogenesis and cell migration[5][6].
  • May reduce inflammation and fibrosis indirectly via thymosin pathways observed in animal models[11].
  • Generally well tolerated in veterinary studies; occasional mild injection‑site reactions (redness, tenderness) reported.
  • Human safety data is limited; no large‑scale clinical trials have been completed for TB‑500 specifically[13].

References

For laboratory and research use only. Minimum 98% purity. Not intended for human or animal consumption, medical, diagnostic, therapeutic or veterinary use. These statements have not been evaluated by the MHRA or FDA. This protocol is provided for educational and research purposes only and is not medical advice. The purchaser accepts full responsibility for safe handling, storage and lawful use.